Their innovative approach goes beyond genome editing to directly modify the proteome, offering a First in Class solution for protein editing. With a single suppressor tRNA therapy, hC Bioscience aims to correct multiple mutant proteins in a wide range of disease indications, providing a fast and efficient path to value. The brand's proprietary tRNA based technology is rooted in solid biologic and therapeutic principles, making it a promising avenue for precision medicine.

By harnessing the power of engineered tRNAs, hC Bioscience is able to address disease-causing issues in the genetic code and overcome protein dysfunction. At hC Bioscience, their focus is firmly set on serving the needs of patients and their families through transformative medicines. They are driven by a mission to create innovations in precision protein editing therapies for genetically defined diseases, with the ultimate purpose of transforming patients' lives by targeting protein dysfunction.

Led by a team of experienced professionals, including Co-Founder, President & CEO Leslie J. Williams, hC Bioscience combines expertise in building companies, raising funds, and negotiating strategic collaborations to drive their vision forward. Supported by a dedicated Board of Directors and a distinguished Scientific Advisory Board, the brand is well-positioned to make significant contributions to the field of protein editing.

By partnering with various organizations and acquiring cutting-edge technologies, such as their recent collaboration with 4SR Biosciences, hC Bioscience is expanding their platform development to further advance the development of first-in-class tRNA-based therapeutics. With their relentless pursuit of scientific excellence and commitment to patient care, hC Bioscience is at the forefront of protein editing technologies, aiming to create a brighter future for patients with genetically defined diseases